Clinical trials: Non-relapsing Secondary Progressive Multiple Sclerosis
- Condition Non-relapsing Secondary Progressive Multiple Sclerosis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi